Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) dropped 0% during trading on Friday . The company traded as low as $0.56 and last traded at $0.58. Approximately 75,969 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 672,492 shares. The stock had previously closed at $0.58.
Wall Street Analysts Forecast Growth
Separately, Alliance Global Partners downgraded shares of Matinas Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st.
Check Out Our Latest Stock Analysis on MTNB
Matinas Biopharma Stock Performance
About Matinas Biopharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Read More
- Five stocks we like better than Matinas Biopharma
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Market Cap Calculator: How to Calculate Market Cap
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
